A combination of local consolidation therapy and EGFR-TKIs in patients with oligometastatic NSCLC harboring EGFR activating mutations significantly prolonged PFS and overall survival (OS), relative to TKIs alone (11). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.